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Abstract
Background: Effective mass drug administration (MDA) with anti-malarial drugs can clear the human infectious
reservoir for malaria and thereby interrupt malaria transmission. The likelihood of success of MDA depends on the
intensity and seasonality of malaria transmission, the efficacy of the intervention in rapidly clearing all malaria
parasite stages and the degree to which symptomatic and asymptomatic parasite carriers participate in the
intervention. The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP)
plus artesunate (AS) plus primaquine (PQ, single dose 0.75 mg/kg) on malaria transmission was determined in an
area of very low and seasonal malaria transmission in northern Tanzania.
Methods: In a cluster-randomized trial in four villages in Lower Moshi, Tanzania, eight clusters (1,110 individuals; cluster
size 47- 209) were randomized to observed treatment with SP+AS+PQ and eight clusters (2,347 individuals, cluster size
55- 737) to treatment with placebo over three days. Intervention and control clusters were 1km apart; households that
were located between clusters were treated as buffer zones where all individuals received SP+AS+PQ but were not
selected for the evaluation. Passive case detection was done for the entire cohort and active case detection in 149
children aged 1-10 year from the intervention arm and 143 from the control arm. Four cross-sectional surveys assessed
parasite carriage by microscopy and molecular methods during a five-month follow-up period.
Results: The coverage rate in the intervention arm was 93.0% (1,117/1,201). Parasite prevalence by molecular
detection methods was 2.2-2.7% prior to the intervention and undetectable during follow-up in both the control
and intervention clusters. None of the slides collected during cross-sectional surveys had microscopically detectable
parasite densities. Three clinical malaria episodes occurred in the intervention (n = 1) and control clusters (n = 2).
Conclusions: This study illustrates the possibility to achieve high coverage with a three-day intervention but also
the difficulty in defining suitable outcome measures to evaluate interventions in areas of very low malaria
transmission intensity. The decline in transmission intensity prior to the intervention made it impossible to assess
the impact of MDA in the chosen study setting.
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Background
Recent reports on a reduction of malaria transmission in
several parts of sub-Saharan Africa [1-7] have resulted in
optimism about the possibility to eliminate malaria
in some malaria endemic areas [8,9]. Significant reduc-
tions in the number of clinical malaria cases were attribu-
ted to the wide-scale implementation of vector control
measures [1,2,10,11], high coverage of insecticide-treated
bed nets [1,2,4,6,10,11] and the introduction of effective
artemisinin combination therapy (ACT) [1-3,6,12]. ACT
has excellent cure rates in sub-Saharan Africa [13] and
has an additional advantage of reducing malaria trans-
mission in comparison to previous first-line treatments
[14-20]. However, even at very low levels of transmission
intensity, the employment of ACT in the first-line treat-
ment of malaria may not result in the elimination of
malaria [15]. This is because the impact of treatment on
transmission intensity is greatly influenced by the pro-
portion of parasite carriers that carry the infection
asymptomatically and that are therefore unlikely to seek
anti-malarial treatment [18]. Asymptomatic parasite car-
riers form an important source of infection to mosqui-
toes [21-26] and frequently harbour parasites at densities
below the microscopic detection limit [14,27-31]. Sub-
microscopic parasite carriage may be most relevant for
malaria transmission in areas of low endemicity, where
the relative proportion of parasite carriers that are missed
by microscopy is greatest [30]. These low-density infec-
tions should therefore be included in interventions that
aim to target the human infectious reservoir.
There are two possible approaches to include asympto-
matic carriers in treatment campaigns: i) mass-screening
and treatment of all parasite carriers (MSAT) and ii) mass
treatment without prior screening for parasitaemia, i.e.
mass drug administration (MDA). Large-scale and rapid
detection of sub-microscopic parasite densities under field
conditions is currently complicated [27] primarily due to
the sensitivity and turn-around time of the tests available.
An MDA approach may, therefore, be the most straight-
forward method. Several MDA interventions were under-
taken in the late 1950’s when the World Health
Organization recommended MDA as a tool for malaria
control when other methods had failed (reviewed in [32]).
Despite successes of MDA in isolated areas [33,34], posi-
tive but not always well-documented experiences from
China (described in [35]) and a report from Cambodia
suggesting that ACT treatment campaigns contributed
towards a large reduction in transmission intensity [35],
no MDA programme has succeeded in eliminating malaria
or leading to a sustainable reduction in the burden of
malaria in areas in sub Saharan Africa [32,36].
Despite these sobering results in the past, there is cur-
rently a renewed interest in MDA [15,35] because of the
previous successes in malaria control [1-6]; highly effica-
cious anti-malarial drugs with a transmission reducing
potential [14-20,37] and new insights in the nature of
malaria transmission using sensitive parasite detection
methods [27]. Mathematical modelling has shown that
malaria transmission is, in theory, susceptible to mass
treatment programmes if all subjects within an endemic
community could be given anti-malarials that clear para-
sitaemia during a period of absent or very low vector
densities in areas where the intensity of transmission is
already low [38,39]. The current manuscript reports on a
cluster-randomized trial of MDA with a gametocytocidal
drug combination of an ACT combined with primaquine
in an area of very low transmission intensity in Tanzania.
Methods
Study area and participants
This study was conducted in the area of Lower Moshi
(latitude 3°61’-3°68’S; longitude 37°32’-37°38’E), northern
Tanzania. The area of Lower Moshi lies on an altitude of
~700 meter between the Maasai savannah and foothills
of Mount Kilimanjaro. In 2005, malaria transmission was
hypoendemic with an estimated entomologic inoculation
rate of 3.4 (95% CI 0.7-9.9) infectious bites per person
per year [40]. Mosquitoes are practically absent in the
period January-March and more prevalent in March-May
and October-November following seasonal rains [40].
Four villages were included in the current study: Kiruani,
Majengo, Magadini and Korongo. The total population
was 5,094 inhabitants, as determined by a census several
weeks before the intervention.
Consenting procedure and ethical issues
Consent was obtained at three levels. Firstly, village
meetings were organized 4-5 months prior to the inter-
vention. During these meetings the study was explained
to all village leaders and local ten-cell leaders (represen-
tatives of approximately 10 households, balozi’s) and ver-
bal approval was obtained from these local leaders. The
necessity to allow individual households and household
members to decide on participation was also explained in
order to minimize the binding influence of local authori-
ties. Secondly, verbal household consent was obtained
2-3 months before the intervention during a final census
visit in which each household was visited, members were
enumerated and their name, gender and age recorded.
During this census visit the purpose of the study, its pro-
cedures and the practical consequences of participation
were explained in detail to all adult household members.
Participant information sheets were provided to each
head of household and the same information was posted
at central places in the village on poster format. Thirdly,
individual consent was obtained on the day of the
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intervention. Prior to drug administration, written con-
sent was obtained from all literate adults, literate house-
hold members were asked to sign for consenting illiterate
adults. Parents or guardians were asked to consent for
children (aged 1-18 years); written consent was also
asked for children aged ≥ 10 years. Ethical approval was
given by the ethical board of the Tanzanian National
Institute of Medical Research (NIMR/HQ/R.8a/Vol. IX/
491) and the Tanzanian Food and Drug Authority
(CE.57/180/01/8).
Cluster definition and randomisation
All households and structures in the study area were
geo-located using a hand-held global positioning system
unit (Trimble GeoExplorer III, California, US). Sixteen
geographical clusters were defined using ArcGIS 9.1
(ESRI, Redlands, CA, US), see Figure 1. Where possible,
clusters were based on geographically confined groups
of households. There was no minimum or maximum
population size of clusters but the minimum distance
between clusters was set at 1 km, based on the average
dispersal range of anophelines in densely populated
African settings [41-43]. Clusters were randomized to
the intervention or control arm using computer gener-
ated randomisation tables using excel (MS Excel, Micro-
soft Corp., Seattle, US).
Households that were located between clusters (i.e.
within 1 km distance from the boundary of intervention
and/or control clusters) were considered as buffer zones.
Members of these households received the intervention
in order to minimize contamination of parasite carriage
in the vicinity of intervention clusters, but were not
included in the evaluation of the MDA.
Intervention arms
Control arm
Inhabitants of clusters randomized to the control arm
received placebo tablets (lactose tablets, Albocin® Glaxo
Smith Kline, Brentford, UK) once daily over three days.
Placebo tablets were of a different size and colour than
the tablets used in the intervention arm.
Intervention arm
inhabitants of clusters randomized to the intervention arm
received a combination of sulphadoxine-pyrimethamine
(25 mg sulphadoxine + 1.25 mg/kg pyrimethamine as sin-
gle dose on the first day; Fansidar®, Roche, Switzerland),
artesunate (4 mg/kg/day for three days; Arsumax®, Sanofi,
France), and primaquine (0.75 mg/kg primaquine as single
dose on the third day of treatment in conjunction with the
last dose of AS; Tiofarma BV, the Netherlands). Several
exceptions were made for safety reasons: i) children below
one year of age received no anti-malarial drugs; ii) indivi-
duals who had received a full dose of ACT in the two
weeks before the intervention received no anti-malarial
drugs; iii) pregnant women were not eligible for PQ or AS
and received SP (25 mg sulphadoxine + 1.25 mg/kg pyri-
methamine as single dose on the first day; Fansidar®,
Roche, Switzerland) + amodiaquine (10 mg/kg Camo-
quine® once daily for 3 days; Pfizer, Dakar, Senegal); iv)
anaemic individuals (detailed below) received SP+AS only.
Treatment administration
Seven study teams consisting of one medically-trained
individual (medical doctor or medical officer) and one or
two field workers were responsible for consenting,
screening participants for the safety criteria described
above and administering drugs. Several central places
were selected in a village, typically the house of the balozi
or a nearby building. All treatment was given under
direct supervision with food to minimize gastro-intestinal
complaints. Individuals were treated based on age-groups
(Table 1), after average weight for age was determined in
cross-sectional surveys that included 2753 individuals as
described elsewhere [28,44].
Women between 15 and 45 years of age were offered a
pregnancy test before treatment was given (SP+AS+PQ
for non-pregnant, SP+AQ for pregnant women). If nail
bed, palms or conjunctiva were pale, the latter examined
with a colour scale [45], people were considered clinically
anaemic. In children below 12 years of age, where anae-
mia was most common [28], haemoglobin was measured
by HemoCue photometer [Angelholm, Sweden] and
anaemia was defined as an Hb < 8 g/dL. (Clinically) anae-
mic individuals received SP+AS instead of SP+AS+PQ.
The intervention took place in a total period of 16 days,
3-5 weeks before the start of the transmission season
(Figure 2). All balozi’s (representatives of ~10 house-
holds) were involved in the monitoring of movement of
people in the study area. If people newly arrived in the
months following the intervention, balozi’s contacted the
study team that promptly administered the treatment
according to household allocation. A random selection of
children below 12 years of age were monitored actively
for adverse events [44]; for the rest of the population
adverse events were monitored passively. The likelihood
that adverse events were related to the intervention was
assessed based on known previously reported side-effects
of the study drugs (including a-specific allergic reactions)
and the timing of symptoms in relation to drug adminis-
tration. Conventional definitions of severity (adverse
events, serious adverse events) and relatedness (unre-
lated, unlikely, possible, probable and definite) were used.
Objective
To determine the impact of a single round of mass drug
administration with a gametocytocidal drug combination
on malaria transmission in Lower Moshi, an area of low
and seasonal malaria transmission.
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Outcome measures
Outcome measures were the impact of MDA on
i) malaria morbidity by active and passive case detection;
ii) asexual parasite prevalence and density by micro-
scopy, rapid diagnostic test and molecular detection
methods; iii) gametocyte prevalence and density by
microscopy and molecular detection methods; iv)
transmission intensity quantified by the entomologic
inoculation rate.
Malaria morbidity by active and passive case detection
The impact of the intervention on malaria morbidity
was assessed by active and passive case detection. Three
health facilities in the study area were involved in
Figure 1 The study villages of Kiruani, Majengo, Magadini and Korongo. Each village is presented separately. The north-south arrow relates
to the position of households within a village, not to the relative location of villages. Each dot represents a household, dark dots represent
intervention households; open dots control households. Buffer zones are depicted in transparent grey. The intervention (I) and control (C)
clusters are numbered.
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passive case detection. Each household was provided
with a household identification card that contained the
names of household members, information on their sub-
village, village leader and household number that
allowed geo-locating the households. With this house-
hold identification card, all household members were
entitled free access to treatment at the health facilities.
Upon arrival at the health facility, household number,
name, age and gender were recorded by the responsible
medical doctor or clinical officer. Temperature was
measured and a slide and rapid diagnostic test (RDT)
prepared. Diagnosis was based on the RDT result and
parasitaemic individuals with (history of) fever were
treated with artemether-lumefantrine according to
national guidelines. For active case detection, 150 chil-
dren (aged 1-10 years) from intervention clusters and
150 children (aged 1-10 years) from placebo clusters
were randomly selected to be followed-up for six
months. Caretakers of these children were provided
with a simple symptom diary and asked to record the
daily occurrence of fever, headache and body pains.
Every fourteen days a trained fieldworker visited the
child, examined their symptom diary and measured
their temperature. In case of (history of) fever, an RDT
was used to determine the presence of parasites. Parasi-
taemic children and all children with current fever were
transported to the nearest health facility for clinical care
and, in case of a positive RDT, confirmation of parasi-
taemia by microscopy.
Parasite carriage in cross-sectional surveys
A cross-sectional survey was conducted in January-
February, several weeks before the intervention. Four
cross-sectional surveys were conducted to evaluate the
impact of the intervention in April-July. On each occa-
sion, 50 individuals from each cluster were individually
selected from computer generated random tables and
invited to a central point in one of the four sub-
villages. A short questionnaire was administered and
participants were asked to provide a blood sample for
i) rapid diagnostic test (RDT, Paracheck® Orchid Bio-
medical Systems, Goa, India); ii) blood slide; iii) serol-
ogy from filter paper (3 MM Whatman, Maidstone,
UK); iv) extraction of nucleic acids from filter paper
(903 Protein Saver Card, Whatman, Maidstone, UK);
v) hemoglobin concentration by HemoCue photometer
(HemoCue, Angelholm, Sweden). Diagnosis was based
on the RDT; those positive by RDT with (a history of)
fever were treated with artemether-lumefantrine (Coar-
tem®, Novartis, France) according to national
guidelines.
Slides were Giemsa-stained and read by two indepen-
dent microscopists, each examining 100 high power fields
before declaring a slide negative. If parasites were
detected, these were enumerated against 200 white blood
cells and converted to parasite density/μL assuming
8,000 white blood cells/μL of blood.
Exactly 50 μL of blood was blotted onto filter paper
(903 Protein Saver Card, Whatman Maidstone, UK),
dried overnight and stored with silica gel at -20°C.
Nucleic acids were extracted following the procedure of
Boom et al [46], as described for filter paper by Mens
et al [47]. RNA samples were tested by quantitative
nucleic acid sequence based amplification (QT-NASBA)
on a NucliSens EasyQ analyzer (bioMérieux, Boxtel, the
Netherland) for 18S rRNA parasite detection as described
elsewhere with a sensitivity of ~20 parasites/mL [48]; 18S
rRNA is present in all asexual parasites and gametocytes.
The time to positivity, i.e., the time point during amplifi-
cation at which the number of target amplicons detected
exceeded the mean for three negative controls plus 20
standard deviations, was calculated. Those positive in
the 18S QT-NASBA, were scheduled for testing in the
Table 1 Drug treatment in the intervention arm by age
category
Age Average weight, median (IQR) SP AS PQ
1-2 y 11.0 (9.5 - 11.6) 250/12.5 25 7.5
3-4 y 12.9 (11.5 - 14.5) 500/25 50 15
5-7 y 16.7 (14.8 - 19.0) 500/25 75 15
8-11 y 23.0 (20.5 - 27.1) 750/37.5 100 22.5
12-14 y 33.7 (28.0 - 38.8) 1000/50 125 22.5
15-16 y 43.3 (38.4 - 54.0) 1000/50 150 30
17-18 y 52.5 (47.9 - 56.5) 1250/67.5 200 37.5
> 18 y 54.0 (46.0 - 61.5) 1500/75 200 45
IQR = interquartile range; SP = sulphadoxine-pyrimethamine; AS = artesunate;
PQ = primaquine. SP tablets were given as the nearest complete tablet; AS as
the nearest ½ tablet; PQ tablets were given as 7.5 mg or 15 mg tablets or a
combination.
Figure 2 Seasonality, entomology and timing of the
intervention. Rainfall data is given in the dashed line in mm/week;
the average number of female anophelines caught per night in five
sentinel houses in Kiruani is represented by solid diamonds; the
average number of female anophelines caught per night in ten
sentinel houses in Magadini and Korongo is represented by open
diamonds. The drug intervention was completed 3-5 weeks before
the start of the rains in early April.
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gametocyte specific Pfs25 QT-NASBA, that has a detec-
tion limit of 20-100 gametocytes/mL [48]. For an initial
analysis, 150 samples were randomly selected from the
pre-intervention survey (75 intervention and 75 control
arm) and 100 samples per follow-up cross sectional sur-
vey (50 intervention and 50 control arm).
Transmission intensity by entomological inoculation rate
Mosquitoes were collected in the period October 2007 -
July 2008 in the sub-villages Korongo, Magadini and
Kiruani. Ten households were selected from each sub-
village, 5 from the intervention and 5 from the control
clusters for each village. Households were selected to be
representative of the typical housing structures in the
villages, mud wall and corrugated iron roof. Mosquitoes
were caught with a standard Centre for Disease Control
light traps (CDC, Atlanta, USA). Traps were hung at the
end of an occupied bed with a bed net that was newly
provided by the investigators. Traps were set for 12
hours, from 7 pm to 7 am [49]. In the morning, traps
were then collected and mosquito species determined
and counted. Male anophelines and Culicines were dis-
carded. Female Anopheles mosquitoes were stored on
silica gel for circumsporozoite protein (CSP) ELISA as
described by Wirtz et al [50]. Samples were prepared
individually and assayed in batches of five with positive
batches re-assayed as single mosquitoes. Insectary-reared
unfed female Anopheles mosquitoes were used as nega-
tive controls with the kit supplied CSP antigen as posi-
tive control. Samples were read by eye and on an ELISA
plate reader at 495 nm. The Entomologic Inoculation
Rate was calculated per person per year [51].
Sample size considerations
The number of clusters needed for the evaluation was
based on the expected baseline parasite prevalence by
18S QT-NASBA of 30% [28] and a 1:1 allocation over
intervention and control arms. A pilot study indicated
that parasites were cleared completely within 14 days
[37] and it was assumed that MDA would reduce para-
site carriage in the intervention clusters to below 10%.
Including 50 individuals per cluster in the post-interven-
tion cross-sectional surveys and assuming a conservative
estimate of k (0.5 coefficient of variation of true propor-
tions between clusters within each group), 8 clusters per
intervention arm were needed (Za/2 = 1.96; Zb = 0.84).
To be able to detect temporal variation in efficacy, the
study aimed to collect 50 observations per cluster in the
early transmission season (April-May) and 50 in the late
transmission season (June-July). The number of children
included in active case detection was based on an
expected malaria incidence of 0.5 malaria episode/child/
year in the control arm and a tenfold lower incidence in
the intervention arm. Enrolling 150 children per
treatment arm for six months would result in 900 per-
son-months per arm, giving 80% power to detect the
specified outcomes after, adjusting for correlation
between observations from the same cluster.
Statistical analysis
Parasite prevalence by microscopy and molecular meth-
ods was compared between study arms using Generalized
Estimating Equations (GEE) to account for correlations
between observations from the same cluster and the
same survey. Poisson regression was used for the com-
parison of malaria incidence between the intervention
and control arm, using GEE to account for correlations
among children residing in the same cluster.
Results
Participant flow
The total population of the study area comprised 5,094
individuals living in 1,253 households. Sixteen clusters
were generated, consisting of 55 to 737 individuals.
Eight clusters with a total of 1,110 individuals were ran-
domized to receive the intervention, eight clusters with a
total of 2,347 individuals were randomized to receive pla-
cebo (Table 2). The three largest clusters with 737, 649
and 525 individuals were all randomized to the placebo
arm, explaining the difference in population size between
the two treatment arms. Of those eligible 96.8% (993/
1,026) received at least one dose of the gametocytocidal
drug combination, 96.5% (990/1,026) received two doses
and 95.3% (978/1,026) received three doses although 35 of
these were excluded from PQ treatment because of a mea-
sured Hb < 8 g/dL (Figure 3). Twenty-seven women were
pregnant; 25 of them received alternative malaria medica-
tion with SP+AQ.
A total of 91 individuals (25 children < 15 years, 3 chil-
dren < 1 year) arrived in an intervention area and 114
individuals (41 children < 15 years; 6 children < 1 year)
arrived in a placebo area after the intervention took place
(Table 2); all agreed to take the drugs their area of resi-
dence was allocated to within two weeks of arrival and
under supervision. 94.3% (1,132/1,201) of the total popula-
tion of the intervention clusters, including newcomers and
pregnant women (receiving alternative medication)
received at least one dose and 93.0% (1,117/1,201) of these
received a complete dose of efficacious anti-malarial drugs
in the month preceding the start of the transmission sea-
son or immediately upon arrival in the area.
Adverse events
One individual was diagnosed to have a severe skin
reaction in the week following the intervention. On
review of the study physician this was assessed to be
possibly drug-related. A second individual presented
with skin hyper-pigmentation on the face; this was
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judged to be non-related to drug exposure. Both indivi-
duals were treated with steroid and closely observed
until symptoms disappeared. Haemolytic effects of the
intervention were described in detail elsewhere [44].
Briefly, statistically significant but asymptomatic and
transient haemolysis was observed in children who were
specifically monitored for this side effect. Haemolysis
was most pronounced in G6PD deficient individuals
[44].
The impact of MDA on malaria morbidity
Passive case detection was carried out in the period Febru-
ary-July, during which 405 individuals attended the clinic
with fever and suspected malaria. All individuals were
screened for malaria parasites by rapid diagnostic test and
microscopy. Two malaria cases were confirmed by micro-
scopy and RDT during passive case detection: a 65-year
old man with a parasite density of 4,951 parasites/μL and
a 32-year old woman with an asexual parasite density of
800 parasites/μL and 16 gametocytes/μL. Both individuals
resided in control clusters. Active case detection was done
for 149 children below 10 years of age residing in interven-
tion clusters and 143 children of the same age from con-
trol clusters. One child from an intervention cluster was
identified with reported fever and a parasite density of 240
parasites/μL. None of the malaria cases reported travelling
in the month prior to their symptoms.
The impact of MDA on malaria parasite prevalence
Parasites were detected by microscopy in 1.9% (95% CI
1.4-2.5) of the individuals by microscopy and 32.5%
(95% CI 28.2-37.0) of the individuals by QT-NASBA in
2005 [28] (Table 3). In the pre-intervention cross-sec-
tional survey, parasites were detected in 0.0% (95% CI
0.0-1.0) of the individuals by microscopy and 2.8% (95%
CI 0.8-6.9) by QT-NASBA. In all post-intervention sur-
veys, parasites were not detected in any of the examined
slides (0/2434) and in only six of the examined blood
spots (1.1%, 6/537) examined by QT-NASBA. After this
initial evaluation, the laborious and costly parasite detec-
tion by QT-NASBA was stopped because it was evident
that the study was underpowered to detect differences
in parasite carriage between intervention and control
clusters.
The impact of MDA on malaria transmission intensity
A total of 14,586 mosquitoes were caught in 491 trapping
nights in the intervention clusters and 10,944 during 478
trapping nights in the control clusters. The seasonality of
mosquito exposure is presented in Figure 2. Only one
mosquito from a control cluster in Kiruani (May) was
found to be infected with sporozoites (0.004%, 1/24,528),
resulting in an estimated EIR for the study area of 0.63
infectious bites per person per year.
Discussion
The current manuscript describes the first MDA study on
the African continent since 1999 [36]. A coverage of 94%
with at least one dose of anti-malarials was achieved; 93%
with the full per protocol dose of three drugs given over
three days. Despite this high participation rate, no impact
of MDA on malaria transmission was observed. Parasite
prevalence rates before and after the intervention, by
microscopy and PCR, were too low to allow conclusions
on the impact of the intervention.
The success of MDA depends on its capacity to reduce
the prevalence of pathogens below a critical threshold
level where re-emergence is unlikely and control can be
maintained [52]. For malaria, this threshold prevalence is
very low; the basic reproductive number (R0), the number
of secondary episodes arising from a single infectious
human case in a fully susceptible population, can be well
over 100 if malaria vectors are present [53]. The chance of
achieving this threshold is highest when parasites are
cleared from the human population towards the end of
the dry season when very few mosquitoes are present [38].
The MDA intervention was completed three weeks before
the increase in mosquito numbers following the seasonal
rains and used a gametocytocidal drug combination of SP
+AS+PQ that clears gametocytes in an average of 6.3 days;
significantly quicker than after ACTs alone [54]. Despite
the demanding three-day dosing scheme and logistical
challenges to exclude pregnant women from treatment
with AS and PQ [55,56], our coverage was high compared
to that of previous malaria MDAs. Of the total population
living in intervention clusters, 94% received at least one
dose and 93% received a complete dose of efficacious anti-
malarial drugs in the month preceding the start of the
transmission season or immediately upon arrival in the
Table 2 Baseline data
Intervention (8 clusters) Placebo (n = 8 clusters)
Present at the time of the intervention 1,110 2,347
Arrived in the study area after the intervention 91 114
Proportion female, % (95% CI) 50.0 (47.0 - 53.1) 49.2 (47.2 - 51.1)
Age, median (IQR) 12 (5 - 26) 16 (6-32)
Parasite positive by rapid diagnostic test, % (95% CI) 0.4 (0.0 - 2.0) 1.0 (0.1 - 3.4)
Parasite positive by microscopy, % (95% CI) 0.0 (0.0 - 1.3) 0.0 (0.0 - 1.8)
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area. In The Gambia in 1999, a coverage rate of 73% was
achieved after one and of 88% after two rounds of drug
administration. The drug combination given was SP plus a
single dose of AS, given on a single day [36,57]. Coverage
of other reported MDA campaigns in Uganda (50%) [34],
Nicaragua (70%) [58] and Garki, Nigeria (85%) [59] were
lower than that in the current setting. The successful
malaria eradication campaign on Aneityum, Vanuatu,
 
Intervention (n=1,110) 
Clusters (n=8) 
Total population, n=5,094 
♦treated in buffer zones, n=1,637 
♦eligible for randomization, n=3,457

Control (n=2,347) 
Clusters (n=8) 
Clusters (n=16) 

Passive case detection: 1,201 individuals, 7 months 
Active case detection: n=149, 1043 person-months 
Cross-sectional surveys, n=1303 observations 
 Jan-Feb n=284; Apr n=261; May n= 227; Jun n= 172; 
Jul n=360 
Eligible, n=1,026 
Not eligible, n= 84 
♦Pregnant (n= 27, 25 received alternative drug)
♦Below 1 year of age (n=26, received no drugs) 
♦Allergic to sulphadoxine-pyrimethamine (n=3) 
♦Received full dose of antimalarials <14d (n=23) 
♦ Unable to consent (mental illness, n=2; alcoholic, n=4) 

Refused completely, n= 33 
♦Religious reasons (n= 5)
♦No reason given (n=27)
Passive case detection: n=2,461, 7 months 
Active case detection: n=143, 1001 person-months 
Cross-sectional surveys, n=1130 observations 
Jan-Feb n=212; April n 223; May n=223; June n=172;  
Jul n=300 
Refused completely, n= 84 
♦Religious reasons (n= 3)
♦No reason given (n=81)
Eligible, n=2,268 
Not eligible, n= 79 
♦Below 1 year of age (n=70, received no drugs) 
 ♦Unable to consent (alcoholic, n=9) 

Treated with gametocytocidal drug combination:  
Received dose 1 under supervision, n=993 
Received dose 1-2 under supervision, n=990
Received dose 1-3 under supervision, n=978 (35 no PQ) 
Treated with placebo:  
Received dose 1 under supervision, n=2,184 
Received dose 2-3, n=2,184 (no supervision) 

Arrived after the initial intervention (n=91):  
Received dose 1 under supervision, n=91 
Received dose 1-2 under supervision, n=91
Received dose 1-3 under supervision, n=91 (3 no PQ) 
Arrived after the initial intervention (n=114):  
Received dose 1 under supervision, n=114 
Received dose 2-3 under supervision, n=114
Figure 3 Participant flow chart.
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used 9 rounds of MDA in a population of 718 individuals
with participation rates of 79-92% for each round [33].
The maximum number of tablets that had to be taken by
adults on Aneityum was 13 on a single day, compared to 7
per day on the first two days and 10 on the third day in
the current study. Although this indicates that a compli-
cated dosing scheme and high tablet number do not pre-
clude high participation rates, the number of tablets was
mentioned as burdensome by some participants (Sheka-
laghe, unpublished data) [33,60].
The intervention strategy that involved local village lea-
ders and village representatives as part of the interven-
tion teams is likely to have contributed to the high level
of community participation [60]. The stepwise consent
procedure and repeated village meetings gave inhabitants
of the study area sufficient time to consider participation
and opportunities to raise questions. A study on commu-
nity perceptions of MDA in The Gambia concluded that
knowledge about malaria was related to a higher indivi-
dual participation rate and that people who had discussed
the study with other villagers and those who understood
the necessity for a high participation rate for MDA to
work were also more likely to participate [57]. During
community meetings the necessity for asymptomatic
individuals to participate in order to achieve community
benefits was strongly emphasized, although no attempt
was made to quantify community understanding. The
approach to give local leaders a central role in explaining
the study purposes, drug administration and monitoring
migration will also have influenced the response rate.
Several opinion makers in The Gambia were antagonistic
to the intervention and reduced participation rates [57];
the current study received full participation of all 62
balozi’s in the study area.
Despite its high coverage, no impact of MDA on the
transmission in the area was observed. The study area
was selected for its very low transmission intensity and
marked seasonality with almost complete absence of vec-
tors for several months per year [40]. The site selection
and trial design were based on the assumption of a sub-
microscopic parasite carriage of ≥ 30% [28], that would
maintain malaria transmission in the area [31] and would
form a suitable primary outcome measure for the inter-
vention. Contrary to these expectations, malaria had all
but disappeared from the area prior to the MDA inter-
vention during which no major additional malaria speci-
fic control efforts were undertaken. Considerable
reductions in transmission intensity without evident
underlying causes have been reported across northern
Tanzania [5,61,62]. Reported use of insecticide treated
net (ITN) in this period increased from 25.1% (490/1952)
in 2004 [28] to 36.1% (879/2434) in 2007. If these num-
bers reflected a change in effective ITN use, this could
have resulted in a substantial reduction in parasite preva-
lence in the study area of low endemicity [63] although
coverage remains too low to explain an almost complete
elimination of malaria in the area [64,65]. Presumptive
treatment with ACT could also have contributed to the
decline in transmission intensity. Although treatment
prescribing behaviour in the area was not quantified,
presumptive treatment with artemether-lumefantrine,
introduced as first-line treatment in 2007, was common
practice and will have provided parasitaemic and non-
parasitaemic individuals with a curative dose and effec-
tive prophylaxis for several weeks [18,66]. Rainfall was
unreliable in the period preceding the MDA intervention;
being 34% of the preceding 10-year average in 2004, 35%
in 2005, 116% in 2006 and 66% in 2007. A single treat-
ment campaign for trachoma with azithromycin was
undertaken by a non-governmental organisation with an
unknown coverage level. Azithromycin has some anti-
malarial activity at doses given for trachoma [67]. These
components may all have contributed to the fall in trans-
mission intensity observed. The findings from this study
also illustrate the limited understanding on the impor-
tance of sub-microscopic parasite densities for maintain-
ing stable malaria transmission. In 2005, a large-scale
survey was conducted in the study area and detected
P. falciparum in 32.5% of the general population by PCR
compared to 1.9% by microscopy [28]. The large
Table 3 Parasite carriage before and after the intervention
Asexual parasite carriage Gametocyte carriage
microscope QT-NASBA microscope QT-NASBA
2005 1.9 (1.4-2.5) 32.5 (28.2-37.0) 0.4 (0.2-0.7) 15.0 (11.9-18.7)
2008 Pre-intervention Intervention 0.0 (0-2.1) 2.6 (0.3 - 9.2) 0.0 (0-2.1) ND
Control 0.0 (0-1.7) 2.9 (0.04 - 10.1) 0.0 (0-1.7) ND
Evaluation I Intervention 0.0 (0-1.8) 0.0 (0.0 - 6.5) 0.0 (0-1.8) ND
Control 0.0 (0-1.6) 0.0 (0.0 - 7.2) 0.0 (0-1.6) ND
Evaluation II-IV Intervention 0.0 (0-0.7) 0.0 (0.0 - 2.4 0.0 (0-0.7) ND
Control 0.0 (0-0.5) 1.4 (0.2 - 5.1) 0.0 (0-0.5) ND
Asexual parasite carriage was determined by microscopy, reading 100 microscopic fields, and 18S rRNA-based QT-NASBA that detects all parasite stages at an
estimated sensitivity of 20 parasites/mL. Gametocytes were detected by microscopy, separately reading 100 microscopic fields, and Pfs25 mRNA based QT-NASBA
that is gametocyte specific and has a sensitivity of 20-100 gametocytes/mL. ND = not done
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proportion of sub-microscopic parasite carriers is typical
for areas of low endemicity; in areas where the micro-
scopic parasite prevalence is below 10%, microscopy on
average detects just under a quarter of all parasite car-
riers [30]. Although low-density infections can be highly
efficient in eliciting protective immunity in experimental
infections [68], their dynamics are poorly understood in
endemic settings. Harris and colleagues observed that in
a low endemic area on the Solomon islands, parasites
were carried at microscopically detectable densities by
2.2% of the population of whom > 85% were afebrile. The
majority of parasite carriers in all age groups had para-
sites at densities below 500 parasites/μL and parasite pre-
valence increased almost four-fold when PCR was used
for detection [69]. Low parasitaemia and frequent asymp-
tomatic parasite carriage was also reported for an area of
very low endemicity in Vanuatu where parasite preva-
lence by microscopy was 2-3% and > 80% of the parasite
carriers harboured parasites asymptomatically and at a
densities below 500 parasites/μL or below the micro-
scopic threshold for detection [70]. It is currently
unknown how individuals with limited cumulative expo-
sure to malaria manage to control malaria at low parasite
densities or how long sub-microscopic infections persist.
The average duration of malaria infections has been esti-
mated at 210 days in area of intense malaria transmission
[71] where most infections are microscopically detectable
[30]. The duration and gametocytaemic period of sub-
microscopic infections, that dominate in low endemic
areas, are currently unknown. These factors are crucial in
determining the relative contribution of sub-microscopic
infections, that are sufficient to infect mosquitoes [26,29],
to malaria transmission in a population.
Conclusions
This manuscript reports on the first MDA study in Africa
in more than a decade and achieved an unsurpassed parti-
cipation rate. Malaria transmission had practically van-
ished prior to the intervention, with no microscopic
parasite carriers in ~2,400 slides and < 2% parasite carriage
in the subset of samples that were tested for P. falciparum
by QT-NASBA. Molecular parasite detection methods
form a sensitive alternative to microscopy in low endemic
settings but some important epidemiological and clinical
aspects of sub-microscopic parasite carriage are currently
poorly understood and need elucidation. The current
study indicates that it is complicated to determine the
impact of MDA on malaria transmission as stand-alone
intervention; this requires a study area of very low and sea-
sonal yet stable malaria transmission intensity. Future stu-
dies that aim to determine the impact of MDA in Africa
will need to select areas with a higher pre-intervention
level of malaria transmission intensity than the site in
northern Tanzania where this study was conducted.
Considering the current uncertainties about the stability
and longevity of sub-microscopic parasite carriage, it may
be advisable to base power calculations for these future
MDA studies on microscopic parasite carriage in the
population.
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